Prostatitis pp 158-174 | Cite as

The Treatment of Chronic Bacterial Prostatitis: Principles and Management

Abstract

Chronic bacterial prostatitis (CBP) is a subtle disease, often insidious in its onset, that challenges the acumen as well as the patience and determination of every urologist, when it comes to cure this disease. However, CBP is a clinical entity accurately defined by two basic features: recurrent urinary tract infections (UTIs) and persistence of gram-negative enterobacteria, mainly Escherichia coli, in the prostatic secretion. CBP is probably the most common cause of recurrent UTIs in the male patient because the bacterial pathogen often persists unaltered in the prostatic secretion during antibacterial therapy, frequently insufficient and inadequate, and eventually reinfects the urine after treatment is withdrawn. CBP is mainly a bacteriologic diagnosis and, therefore, sequential bacteriologic localization cultures of the initially voided urine, the midstream urine, and the expressed prostatic secretion (EPS) are essential in reaching the right diagnosis and cannot be replaced by any other method. Demonstration of gram-negative bacteria in the EPS in the presence of sterile initial and midstream urine cultures are highly diagnostic for CBP. Alternatively, a significantly higher bacterial level (of a log or more) in the EPS compared to the initial urethral specimen is also considered diagnostic of CBP.

Keywords

Staphylococcus Azole Carb Amoxicillin Doxycycline 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Anderson RU, Fair WR (1976) Physical and chemical determinations of prostatic secretion in benign hyperplasia, prostatitis and adenocarcinoma. Invest Urol 14: 137–140PubMedGoogle Scholar
  2. Anderson RU, Weller C (1979) Prostatic secretion leukocyte studies in nonbacterial prostatitis (prostatosis). J Urol 121: 292–294PubMedGoogle Scholar
  3. Bergeron MG, Thabet M, Roy R, Lessard C, Foucault P (1985) Norfloxacin penetration into human renal and prostatic tissue. Antimicrob Agents Chemother 28: 349–350PubMedGoogle Scholar
  4. Bologna M, Vaggi L, Forchetti CM, Martini E (1983) Bactericidal intraprostatic concentrations of norfloxacin ( Letter to the Editor ). Lancet 2: 280PubMedCrossRefGoogle Scholar
  5. Carroll PT, Robb CA, Tippett LO, Langsten JB (1971) Antibacterial activity of diaveridine, trimethoprim, and selected sulfonamides in prostatic fluid. Invest Urol 8: 686–694PubMedGoogle Scholar
  6. Cox CE (1989) Ofloxacin in the management of complicated urinary tract infections, including prostatitis. Am J Med 87 Suppl 6C: 61S–68SGoogle Scholar
  7. Dalhoff A, Weidner W (1984) Diffusion of ciprofloxacin into prostatic fluid. Eur J Clin Microbiol 5: 360–362CrossRefGoogle Scholar
  8. Dan M, Golomb J, Gorea A, Braf Z, Berger SA (1986) Concentration of ciprofloxacin in human prostatic tissue after oral administration. Antimicrob Agents Chemother 30: 88–89PubMedGoogle Scholar
  9. Fair WR, Crane DB, Schiller N, Heston WDW (1979) A re-appraisal of treatment in chronic bacterial prostatitis. J Urol 121: 437–441PubMedGoogle Scholar
  10. Frimodt-Moller PC, Dorflinger T, Madsen PO (1984) Distribution of ciprofloxacin in the dog prostate and various tissues. Urol Res 12: 283–286PubMedCrossRefGoogle Scholar
  11. Gombert ME, du Bouchet L, Audicino TM, Berkowitz LB, Macchia RJ (1987) Brief report: prostatic tissue concentrations of ciprofloxacin after oral administration. Am J Med 82 Suppl 4A: 130–132Google Scholar
  12. Granato J J Jr, Gross DM, Stamey TA (1973) Trimethoprim diffusion into prostatic and salivary secretion of the dog. Invest Urol 11: 205–210PubMedGoogle Scholar
  13. Larsen EH, Gasser TC, Dørflinger T, Madsen PO (1986) The concentrations of various quinolone derivatives in the human prostate. In: Weidner W, Brunner H, Krause W, Rothauge CF (eds) Therapy of prostatitis: experimental and clinical data. Zuckschwerdt Munich, pp 40–44Google Scholar
  14. Madsen PO, Kjaer TB, Baumueller A (1976) Prostatic tissue and fluid concentrations of trimethoprim and sulfamethoxazole: experimental and clinical studies. Urology 8: 129–132PubMedCrossRefGoogle Scholar
  15. McGuire EJ, Lytton B (1976) Bacterial prostatitis: treatment with trimethoprim-sulfamethoxazole. Urology 7: 499–500PubMedCrossRefGoogle Scholar
  16. McNeal JE (1968) Regional morphology and pathology of the prostate. Am J Clin Pathol 49: 347–357PubMedGoogle Scholar
  17. Meares EM Jr (1975) Long-term therapy of chronic bacterial prostatitis with trimethoprim-sulfamethoxazole. Can Med Assoc J 112 Suppl: 22S–25SGoogle Scholar
  18. Meares EM Jr (1982) Prostatitis: review of pharmacokinetics and therapy. Rev Infect Dis 4: 475–483PubMedCrossRefGoogle Scholar
  19. Meares EM Jr (1986) Chronic bacterial prostatitis: role of transurethral prostatectomy (TURP) in therapy. In: Weidner W, Brunner H, Krause W, Rothauge CF (eds) Therapy of prostatitis: experimental and clinical data. Zuckschwerdt, Munich, pp 193–197Google Scholar
  20. Meares EM, Stamey TA (1968) Bacteriologic localization patterns in bacterial prostatitis and urethritis. Invest Urol 5: 492–518PubMedGoogle Scholar
  21. Naber KG (1989) The role of quinolones in the treatment of chronic bacterial prostatitis. Infection 19 Suppl 3: S170–S177Google Scholar
  22. Naber KG, Sörgel F, Kees F, Jaehde U, Schumacher H (1989) Pharmacokinetics of ciprofloxacin in young (healthy volunteers) and elderly patients, and concentrations in prostatic fluid, seminal fluid and prostatic adenoma tissue following intravenous administration. Am J Med 87 Suppl 5A: 57S–59SGoogle Scholar
  23. Oosterlinck W, Defoort R, Renders G (1975) The concentration of sulfamethoxazole and trimethoprim in human prostate gland. Br J Urol 47: 301–304PubMedCrossRefGoogle Scholar
  24. Pfau A (1986) Prostatitis: a continuing enigma. Urol Clin North Am 13: 695–715PubMedGoogle Scholar
  25. Pfau A (1991) The treatment of chronic bacterial prostatitis. Infection 19 Suppl 3: S160–S164Google Scholar
  26. Pfau A, Sacks T (1976) Chronic bacterial prostatitis: new therapeutic aspects. Br J Urol 48: 245–253PubMedGoogle Scholar
  27. Pfau A, Perlberg S, Shapiro A (1978) The pH of prostatic fluid in health and disease: implications of treatment in chronic bacterial prostatitis. J Urol 119: 384–387PubMedGoogle Scholar
  28. Reeves DS, Ghilchik M (1970) Secretion of the antibacterial substance trimethoprim in the prostatic fluid of dogs. Br J Urol 42: 66–72PubMedCrossRefGoogle Scholar
  29. Robb CA, Carroll PT, Tippett LO, Langston JB (1971) The diffusion of selected sulfonamides, trimethoprim, and diaveridine into prostatic fluid of dogs. Invest Urol 8: 679–685PubMedGoogle Scholar
  30. Sabbay J, Hoagland VL, Cook T (1986) Norfloxacin versus cotrimoxazole in the treatment of recurring urinary tract infections in men. Scand J Infect Dis Suppl 48: 48–53Google Scholar
  31. Schaeffer AJ, Darras FS (1990) The efficacy of norfloxacin in the treatment of chronic bacterial prostatitis refractory to trimethoprim-sulfamethoxazole and/or carbenicillin. J Urol 144: 690–693PubMedGoogle Scholar
  32. Stamey TA (1980) Urinary infections in males. In: Stamey TA (ed) Pathogenesis and treatment of urinary tract infections. Williams and Wilkins, Baltimore, pp 342–29Google Scholar
  33. Stamey TA, Pfau A (1963) Some functional, pathologic, bacteriologic, and chemotherapeutic characteristics of unilateral pyelonephritis in man. II. Bacteriologic and chemotherapeutic characteristics. Invest Urol 1: 162–172PubMedGoogle Scholar
  34. Stamey TA, Meares EM Jr, Winningham DG (1970) Chronic bacterial prostatitis and the diffusion of drugs into prostatic fluid. J Urol 103: 187–194PubMedGoogle Scholar
  35. Stamey TA, Bushby SRM, Bragonje J (1973) The concentration of trimethoprim in prostatic fluid: Nonionic diffusion or active transport? J Infect Dis 128 Suppl: S686–S690Google Scholar
  36. Weidner W, Schiefer HG, Brähler E (1991) Refractory chronic bacterial prostatitis: a re-evaluation of ciprofloxacin treatment after a median follow-up of 30 months. J Urol 146: 350 - 352PubMedGoogle Scholar
  37. Winningham DG, Nemoy NJ, Stamey TA (1968) Diffusion of antibiotics from plasma into prostatic fluid. Nature 219: 139–143PubMedCrossRefGoogle Scholar
  38. Wright WL, Larking P, Lovell-Smith CJ (1982) Concentration of trimethoprim and sulphamethoxazole in the human prostate gland after intramuscular injection. Br J Urol 54: 550–551PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1994

Authors and Affiliations

  • A. Pfau

There are no affiliations available

Personalised recommendations